Tian Zhang, MD

Assistant Professor of Medicine
Member of the Duke Cancer Institute
Campus mail DUMC 103861, Durham, NC 27710
Phone (919) 668-4667
Email address tian.zhang2@duke.edu

Education and Training

  • Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2012 - 2015
  • Internal Medicine Residency, Medicine, Duke University School of Medicine, 2009 - 2012
  • M.H.S., Duke University School of Medicine, 2019
  • M.D., Harvard Medical School, 2009

Publications

Mi, Yu, Feifei Yang, Cameron Bloomquist, Youli Xia, Bo Sun, Yanfei Qi, Kyle Wagner, Stephanie A. Montgomery, Tian Zhang, and Andrew Z. Wang. “Biologically Targeted Photo-Crosslinkable Nanopatch to Prevent Postsurgical Peritoneal Adhesion..” Adv Sci (Weinh) 6, no. 19 (October 2, 2019). https://doi.org/10.1002/advs.201900809.

PMID
31592414
Full Text

Zhang, Tian, Lawrence I. Karsh, Michael J. Nissenblatt, and Steven E. Canfield. “Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer..” Clin Genitourin Cancer, September 26, 2019. https://doi.org/10.1016/j.clgc.2019.09.015.

PMID
31653572
Full Text

Wang, Hong, Lu Mao, Tian Zhang, Liming Zhang, Yuteng Wu, Wei Guo, Jingzhou Hu, Houyu Ju, and Guoxin Ren. “Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients..” J Oral Pathol Med 48, no. 8 (September 2019): 669–76. https://doi.org/10.1111/jop.12883.

PMID
31132187
Full Text

Labriola, Matthew K., Kristen A. Batich, Jason Zhu, Megan A. McNamara, Michael R. Harrison, Andrew J. Armstrong, Daniel J. George, and Tian Zhang. “Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma..” Clin Genitourin Cancer 17, no. 3 (June 2019): e513–21. https://doi.org/10.1016/j.clgc.2019.01.017.

PMID
30858035
Full Text

Kao, Chester, Megan McNamara, Chris Alley, Neil Spector, Shekeab Jauhari, Rajan T. Gupta, Tian Zhang, and Jason Zhu. “A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder..” Clin Genitourin Cancer 17, no. 3 (June 2019): e672–77. https://doi.org/10.1016/j.clgc.2019.03.019.

PMID
31097390
Full Text

Labriola, Matthew, Jason Zhu, Rajan Gupta, Shannon McCall, Jennifer Jackson, James R. White, Elizabeth Weingartner, et al. “Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC)..” In Journal of Clinical Oncology, 37:e16079–e16079. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e16079.

Full Text

Zhang, Tian, Bridget F. Koontz, Scott T. Tagawa, Himanshu Nagar, Rhonda L. Bitting, Bart Frizzell, Julia Rasmussen, et al. “A phase II Salvage Trial of AR Inhibition with ADT and Apalutamide with Radiation therapy followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (STARTAR)..” In Journal of Clinical Oncology, 37:TPS5097–TPS5097. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.tps5097.

Full Text

Zhu, Jason, Matthew D. Tucker, Chester Kao, Matthew Labriola, Sachica Cheris, Michael B. Datto, Yuan Wu, et al. “Immune checkpoint inhibitor response in tumors with LRP1B variants..” In Journal of Clinical Oncology, 37:e14291–e14291. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e14291.

Full Text

Zhu, Jason, Sarabjot Pabla, Matthew Labriola, Rajan T. Gupta, Shannon McCall, Daniel J. George, Devin Dressman, et al. “Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC)..” In Journal of Clinical Oncology, 37:2595–2595. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.2595.

Full Text

Pages